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ABSTRACT
Spinal anaesthesia for Caesarean section is associated with an unacceptably high 
incidence of hypotension despite the administration of an intravenous fluid preload and 
the use of uterine displacement. The theoretical benefits of preventing hypotension as 
opposed to treating it as it occurs are the avoidance o f considerable maternal 
discomfort, a reduced risk o f serious cardiovascular or respiratory depression and the 
avoidance of transient foetal asphyxia.
The use of prophylactic intramuscular ephedrine prior to spinal anaesthesia has been 
recommended but not well studied. The advantages o f the intramuscular route for 
ephedrine administration are its simplicity and its favourable pharmacokinetic profile. 
Cardiovascular support is sustained throughout the surgery and into the post operative 
period. Opposition to the use o f intramuscular ephedrine in the prevention of 
hypotension is based on two studies in which spinal anaesthesia was not used [1,2]. 
These studies showed an unacceptably high incidence o f hypertension, a deleterious 
effect on foetal gas exchange and a lack of efficacy when intramuscular ephedrine was 
used in epidural and general anaesthesia respectively.
This research report describes a randomised, double blind, interventional study designed 
to assess the safety (prevalence of hypertension, tachycardia or foetal compromise) and 
efficacy (prevalence of hypotension) o f 37,5mg of ephedrine given prior to spinal 
anaesthesia for Caesarean section. Forty patients who had given informed consent were 
entered into the study. Blood pressures and pulse rates were recorded for 90 minutes 
after ephedrine administration, samples o f umbilical venous blood were collected and 
Apgar scores assessed.
This study found that giving 37,5mg of intramuscular ephedrine prior to spinal 
anaesthesia was safe from a maternal point of view in that it was not associated with 
reactive hypertension or tachycardia. When the ephedrine was given 10 minutes prior to 
induction of the spinal the technique proved to be effective in reducing the incidence and 
severity of hypotension. When used in the above manner the technique was not 
associated with foetal depression or acidosis.
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CHAPTER 1
INTRODUCTION
1.1 BACKGROUND TO THE USE OF INTRAMUSCULAR EPHEDRINE IN 
SPINAL ANAESTHESIA
The use of spinal anaesthesia for obstetrical procedures dates back to 1901 but it was 
only in the 1940’s that use of the technique became widespread [3], Although spinal 
anaesthesia was used extensively for Caesarean sections until the late 1960s, associated 
complications including hypotension and post dural puncture headache led to a decline 
in its use in favour of epidural anaesthesia. It is only recently that spinal anaesthesia has 
enjoyed a resurgence of popularity in the obstetrical anaesthesia world and this relates to 
the development o f small gauge needles and newer bevel designs.
Ephedrine was first used to treat and prevent post-spinal hypotension in 1927 [4], The 
use of prophylactic intramuscular vasopressors prior to spinal anaesthesia became widely 
practised in thel950’s [5], However a prospective study published in 1960 detected an 
association between the use of intramuscular vasopressors and severe postpartum 
hypertension [6], The study had been prompted by the occurrence of an intracranial 
haemorrhage two hours postpartum in a patient who had received a prophylactic 
vasoconstrictor prior to caudal anaesthesia. This finding, and a widely quoted study by 
Wollman in 1968 which purported to show the success o f fluid preloading in preventing 
hypotension, led to a decrease in the use o f prophylactic vasopressors [7],
In a review article in Anesthesiology in 1970, Smith and Corbascio declared the “decline 
and fall of the vasopressor” and warned of the danger o f injudicious use of these drugs 
[8], A move towards more physiological methods to control blood pressure under 
anaesthesia was encouraged.
However, in spite of an increased understanding of the pathophysiology of spinal 
anaesthesia and the use of conservative physiological methods (intravenous fluids and 
left lateral position), the incidence of post-spinal hypotension remained unacceptably
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high. Wollman’s results were not borne out by subsequent studies and the focus returned 
to vasopressors for the prevention and treatment o f post spinal hypotension. The 
question became, not whether to use vasopressors, but how to use them. The continuing 
contention revolves around whether to use the vasopressors on a prophylactic or 
therapeutic basis .
Proponents of the prophylactic approach argue that allowing a rapid precipitous fall in 
blood pressure has significant clinical consequences i.e.foetal asphyxia, considerable 
patient discomfort with nausea and vomiting and the potential for respiratory depression 
and electromechanical dissociation [9-11], On the other hand opponents of the 
prophylactic approach criticise the unnecessary administration of vasoactive drugs which 
in some cases would constitute overtreatment. They cite maternal hypertension and 
tachycardia and foetal asphyxia relating to uterine artery vasoconstriction as potentially 
harmful side effects [1,2],
In 1976, in a widely quoted study of a small sample o f patients, Gutsche demonstrated 
the efficacy of combining the physiological methods of intravenous fluid preload and left 
lateral tilt with the pharmacological method of prophylactic intramuscular ephedrine [9], 
Although this technique continues to be recommended by contemporary text books of 
obstetrical anaesthesia [12], considerable prejudice has developed against the use of 
intramuscular ephedrine in neuraxial anaesthesia in pregnancy because of concerns raised 
by two studies.
The first, in 1982 by Rolbin et al, showed a high incidence of reactive hypertension 
when intramuscular ephedrine was used in an epidural context [1]. It should be noted 
that inferences about the cardiovascular effects o f intramuscular ephedrine in spinal 
anaesthesia should not be made from a study o f epidural anaesthesia as the two 
techniques are physiologically and pharmacologically different.
The other more recent study to criticise intramuscular ephedrine in obstetrical spinal 
anaesthesia was published in 1992 by Rout et al [2], They emphasised the problem of 
failing to administer the spinal after giving intramuscular ephedrine and then having to 
convert to general anaesthesia where subsequent reactive hypertension may be
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problematic. Rout et al, not surprisingly, demonstrated reactive hypertension in patients 
given intramuscular ephedrine who received a general, not a spinal, anaesthetic. On the 
basis o f this and because they detected statistically significant (but clinically insignificant) 
acid base changes in umbilical cord blood, they unequivocally condemned the use of 
intramuscular ephedrine in obstetrical spinal anaesthesia.
This study has been designed to assess whether concerns raised by the above studies on 
intramuscular ephedrine apply to the now revived technique o f spinal anaesthesia for 
Caesarean section.
The preferred route of ephedrine administration in South Africa is the intravenous one. 
Intravenous methods could be categorised as prophylactic, early therapeutic or late 
therapeutic. Prophylactic methods comprise either an intravenous bolus directly after the 
spinal is induced or a continuous intravenous infusion titrated to systolic blood pressure 
also commenced after induction of the spinal anaesthetic [10], Early therapeutic 
intravenous treatment implies a small bolus dose as soon as blood pressure declines as 
opposed to the late therapeutic method where an ephedrine bolus is only given when 
systolic blood pressure declines below lOOmmHg or by more than 30% [11],
The disadvantage of the intravenous infusion method relates to its demands in terms of 
effort and equipment particularly in a less sophisticated environment where patient 
turnover is high. The disadvantage of the intravenous bolus method lies in the short 
duration o f action of ephedrine which mandates repeated boluses and frequent and 
prolonged blood pressure monitoring. A recent case report of a cardiac arrest after 
Caesarean section under subarachnoid anaesthesia was causally related to an episode of 
post-operative hypotension [13], In this instance intravenous boluses of ephedrine had 
been used intra-operatively.
The candidate sees theoretical advantage in the intramuscular route for ephedrine 
administration over the intravenous one in its simplicity and its potentially favourable 
pharmacokinetic profile i.e. prolonged uptake results in plasma levels of ephedrine being 
maintained throughout the intraoperative and into the post operative period providing 
sustained and reliable cardiovascular support.
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The purpose o f this dissertation is to re-evaluate a tried and tested technique, and 
possibly prevent it from being abandonedfor the wrong reasons.
1.2 HYPOTENSION AND SPINAL ANAESTHESIA - Maternal and foetal effects
The most important physiological effect o f spinal anaesthesia is hypotension. The 
decrease in arterial pressure is more severe and occurs more rapidly in the pregnant 
patient than in the non-pregnant patient [3], This relates to the so called ‘supine 
hypotension syndrome’ o f pregnancy caused by compression by the gravid uterus o f the 
inferior vena cava, pelvic veins and the aorta. This ‘potential’ syndrome is prevented by 
a reflex increase in neurogenic vasoconstrictor tone. Spinal anaesthesia abolishes this 
compensatory mechanism.
Spinal hypotension results more from dilatation o f veins than of arteries [14]. When 
local anaesthetic agents are injected into the subarachnoid space a preganglionic 
sympathetic denervation occurs. Unlike denervated arteries, denervated veins dilate 
maximally causing gravity dependent peripheral venous pooling. As a result cardiac 
preload decreases, cardiac output decreases and consequently blood pressure decreases
[3]-
The incidence o f hypotension in spinal anaesthesia is less in labouring (approximately 
50%) than in non-labouring patients (approximately 92%) [15], This may be as a result 
of the autotransfusion of the vascular system with approximately 300ml of blood with 
each uterine contraction. It may also relate to the fact that labouring patients are 
receiving intravenous fluid therapy and often oxytocic agents (syntocinon, used to 
increase uterine contraction) whereas non-labouring patients are relatively dehydrated by 
pre-operative starvation.
The degree of sympathetic block tends to be greater, and the onset o f hypotension 
faster, after spinal than after epidural anaesthesia [16], This is because the speed of onset 
of the block is faster than the development o f any physiological compensation.
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The major factor in the development of hypotension is the level o f the block [17], 
Sympathetic outflow is between T1 and L2. Fibres from T2 to T4 provide the 
sympathetic supply to the heart and decreased contractility and bradycardia ( from 
unopposed vagal activity) ensues if they are blocked [17]. A block as high as T1 may 
completely remove the ability o f the body to compensate for other circulatory changes 
and in addition produces extensive vaso- and veno-dilatation. Individual variations in 
technique such as speed of injection or the use o f barbotage maj cause different degrees 
of hypotension by altering the height o f block obtained and the rate at which it develops.
The minimum acceptable blood pressure with regard to maternal and foetal well being 
remains speculative [14], When mean arterial pressure falls below 50mmHg, decreases 
in cerebral blood flow may result in depressed consciousness, depressed respiration and 
nausea and vomiting. An editorial in the Lancet in 1989 suggested that the rapidity with 
which the pressure falls and the symptoms that are produced are probably as important 
as the actual measurement [18],
Cardiac arrest during sub-arachnoid anaesthesia is an uncommon, but well reported 
phenomenon [13], It may relate, in high blocks, to profound bradycardia caused by 
unopposed parasympthetic input. Alternatively, it may be due to decreased venous 
return, which may trigger reflexes mediated by caval and atrial receptors, or result from 
electromechanical dissociation.
Maternal hypotension has been well shown to have a deleterious effect on the foetus.
The uterus autoregulates inefficiently and any decrease in its perfusion pressure results 
in reduced uteroplacental and intervillous blood flow [3], This alters the exchange of 
oxygen, carbon dioxide and nutrients with the foetus. Marx et al., in 1969, showed that 
maternal hypotension causes foetal acidosis [19], These findings have been confirmed by 
subsequent animal and human trials [10,11,20,21],
A study in 1978 showed significant correlation between maternal hypotension (of 4 - 8  
minutes duration ) and weak rooting and sucking reflexes in infants up to 4 - 7 days 
post-delivery [22], In contrast, a subsequent study in 1982, using the Scanlon early 
neonatal neurobehavioural scale showed that a short period o f hypotension (less than 2
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minutes), did not alter neurobehavioural performance despite causing altered neonatal 
acid-base values [23], It is apparent that maternal hypotension only endangers the foetus 
when there is pre-existing foetal compromise or when hypotension is particularly 
profound or prolonged.
The aggressive prevention o f hypotension is prudent, particularly when high spinal 
blockade is deliberately achieved. Hypotension due to spinal anaesthesia causes 
considerable maternal discomfort, nausea and vomiting. Initial mild hypotension may 
progress rapidly to cardiovascular and respiratory collapse. In addition, maternal 
hypotension may cause transient foetal asphyxia.
1.3 EPHEDRINE AND SPINAL ANAESTHESIA - Maternal and foetal effects
Ephedrine is a non-catecholamine sympathomimetic alkaloid [24], It is the active 
principle of the plant MaHuang and has been used for centuries in China. Ephedrine 
stimulates both alphai and betai receptors (having vascular and cardiac effects 
respectively) and acts both directly and indirectly. It may be used intramuscularly as 
local vasoconstriction is insufficient to delay systemic absorption.
Ephedrine is resistant to metabolism by monoamine oxidase (MAO) in the 
gastrointestinal tract so that unchanged drug is absorbed into the circulation following 
oral administration [25], It is also resistant to metabolism by catechol-o-methyl- 
transferase (COMT) thus permitting a relatively long duration o f action. Up to 40% of a 
single dose of ephedrine is excreted unchanged in the urine [25], Some ephedrine is 
deaminated by MAO in the liver where conjugation also occurs [25], This slow 
inactivation and excretion o f ephedrine are responsible for its prolonged duration of 
action. Ephedrine is associated with tachyphylaxis i.e. a second dose produces a less 
intense blood pressure response than the first dose. Tachyphylaxis may relate to a 
persistent blockade of adrenergic receptors by ephedrine or may be due to depletion of 
noradrenaline stores [25],
Ephedrine has been found to have an anti-emetic effect o f its own, without the sedative
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side effects of other anti-emetics. Central nervous system stimulation does occur but to a 
lesser extent than that with other similar drugs such as amphetamines [25],
The role of ephedrine in anaesthesia is in cardiovascular support, particularly after local 
anaesthetic induced sympathetic blockade. This blockade causes venous pooling, 
decreased peripheral resistance, decreased cardiac output, occasionally decreased 
myocardial contractility and decreased heart rate. Ephedrine acts almost as a physiologic 
antagonist to each of these depressant actions.
The cardiovascular effects of ephedrine resemble adrenaline, but its blood pressure 
elevating action is less intense and lasts substantially longer. These effects are due in 
part, to alpha receptor mediated peripheral arterial and venous constriction. The 
principle mechanism, however, for cardiovascular effect is increased myocardial 
contractility as a result o f activation of beta-1 receptors. A study in 1986 demonstrated 
the efficacy of ephedrine in correcting both the venous capacitance and the arterial 
resistance after spinal anaesthesia in a cardiopulmonary bypass-canine model [26], In 
contrast, a study in 1995, found that a low dose infusion of ephedrine caused relatively 
little arterial or venous constriction but increased systolic arterial pressure by increases 
in stroke index and heart rate [21]. The more profound vasoconstrictor effect seen in the 
former study may be accounted for by the higher doses of ephedrine used i.e. 
vasoconstriction is dose related.
Whether or not ephedrine has a deleterious effect on uteroplacental blood flow and 
consequently on the foetus has been a question of some contention. Several animal 
studies have convincingly demonstrated the safety of ephedrine [20,21,28], However, 
human clinical studies have been somewhat contradictory in their findings, particularly 
where ephedrine has been used intramuscularly. Studies by Ward et al., and Gutsche, in 
epidural and spinal anaesthesia respectively, did not demonstrate any adverse effect of 
intramuscular ephedrine on foetal gas exchange [9,29], In contrast, studies by Rolbin et 
al. and Rout et al. both detected adverse changes in umbilical cord acid-base status when 
intramuscular ephedrine was given in epidural and general anaesthesia respectively [1,2]. 
No study has shown reduced Apgar or neurobehavioral scores associated with ephedrine 
administration.
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Two studies have demonstrated foetal and neonatal tachycardia associated with 
ephedrine administration [29,30], However, both agree that there was no evidence that 
these effects on foetal heart rate were due to asphyxia. It is likely that these effects were 
due to the direct action of ephedrine which has been shown to cross the placenta 
extensively.
Ephedrine remains widely accepted as the vasopressor of choice for treating maternal 
hypotension associated with necraxial anaesthesia.
1.4 LITERATURE REVIEW
1.4.1 Vasopressors - the early years.
In 1927 a study by Ockerblad and Dillon introduced the method of using ephedrine to 
prevent hypotension in spinal anaesthesia for urological procedures [4]. They used 
ephedrine lOOmg subcutaneously before systolic pressure dropped below lOOmmHg and 
although they did note an increase in pulse rates, described the technique as “of immense 
practical use in spinal anaesthesia”.
Casady and Moore in 1960 cautioned against the use of prophylactic vasoconstrictors in 
regional anaesthesia for vaginal delivery [6], This was based on a prospective study of 
747 patients who received prophylactic intramuscular methoxamine before continuous 
caudal anaesthesia for vaginal delivery. The patients had also received the oxytocic 
agent ergonovine maleate at the time of placental delivery. It was postulated that the 
combination of vasoconstrictors and oxytocics was associated with severe post 
operative hypertension. Systolic blood pressures of greater than 140mmHg developed in 
4,6% of their patients. The study was terminated when a patient with hypertension 
suffered a ruptured cerebral aneurysm. This event may have resulted in a decline in the 
use of prophylactic administration of vasoconstrictors (the study had been prompted by 
a report of a ruptured intracranial aneurysm 2 hours post delivery in 1957). It should be 
noted that ephedrine was not used in this study and the oxytocics used were ergot 
derivatives with known vasoconstrictor effects.
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In 1962 a retrospective study by Moya and Smith examined the changes in blood 
pressure and pulse rate related to vasopressors, dose of local anaesthetic, level of 
anaesthesia and use of oxytocic drugs [5], They studied the charts of 1633 Caesarean 
sectioned patients over the period 1952 to 1960. They found that 82% of patients had 
received prophylactic vasopressors, 72% of them 50mg of intramuscular ephedrine. In 
spite of this, in 54% of the cases systolic blood pressure had dropped below lOOmmHg. 
This may relate to the fact that 5% dextrose water, which is an ineffective volume 
expander, was used as a fluid preload. They also assessed the incidence of reactive 
hypertension when combining ephedrine with different oxytocics. When ephedrine was 
used with oxytocin, only 1,5% of patients developed an elevation in blood pressure of 
greater than 40mmHg. When ephedrine was used with ergonamine, 5,7% of patients 
developed this degree of hypertension.
In 1965, Greiss and Crandell et al., using a pregnant sheep model, showed that simulated 
hypotension was associated with reduced uterine blood flow [31], They showed that 
certain vasopressor drugs, namely levarterenol, phenylephrine and angiotensin did not 
improve uterine blood flow despite restoring maternal blood pressure. They showed that 
rapid infusions o f 5% dextrose or dextran solutions significantly improved both mean 
blood pressure and uterine blood flow. They suggested that prophylactic or therapeutic 
use of vasopressor agents in pregnancy be contraindicated and recommended therapy 
designed to increase circulating blood volume.
1.4.2 The changing role of fluid preloading.
Wollman and Marx demonstrated the value of fluid pre-loading in spinal anaesthesia in 
1968 [7], In a small study of 14 patients for Caesarean section or vaginal delivery, 
pre-treatment with 1000ml of 5% glucose in Ringer’s lactate solution prevented any 
significant decrease in arterial pressure, whereas the control group all became 
hypotensive. This study is widely quoted and until recently, fluid pre-loading has been 
accepted as a satisfactory method of preventing hypotension. It should be noted that 
43% of their study group patients were in active labour and therefore significantly less 
prone to hypotension. These findings were supported when the following year the same
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group, publishing under Marx, compared the prevention of hypotension to the treatment 
of hypotension with regard to foetal outcome [19]. Significant foetal acidosis (pH 7,18) 
and relatively low Apgar scores were associated with hypotension. They showed better 
foetal biochemical condition and healthier neonates when hypotension was prevented 
than when it was treated. As in their previous study, they emphasised intravenous 
hydration as a preventative measure but did find that a small dose (12,5mg) of 
intravenous ephedrine was a useful adjunct.
Subsequent studies have confirmed Marx’s findings with regard to the effect of 
hypotension on the foetus but have not supported her findings with respect to the 
efficacy of fluid preloading.
In 1976 Clark et al. studied the effects of fluid loading and left uterine displacement in 
the prevention o f hypotension [15]. They achieved left uterine displacement with a 
‘sluder’ (sustained left uterine displacer).They showed an incidence of hypotension of 
92% when no preventive measures were taken in patients for elective Caesarean section. 
With fluid loading and left lateral tilt combined, the incidence was reduced to 53%, and 
with fluid loading alone, to 57%. Thus although these conservative methods reduced the 
incidence of hypotension, the incidence remained unacceptably high. Clarks’ findings 
conflicted with those of Wollman et al., who showed no significant change in mean 
arterial pressure after a preload of one litre of Ringer’s lactate solution. Clark et al. 
comment that Wollman et al’s use of mean pressure in their study may have obscured 
the fact that systolic pressure could fall below lOOmmHg. It was also notable in this 
study that patients in labour had significantly lower incidences o f hypotension (50%) 
than patients out of labour (92%). This was reduced to 14,7% with fluid preloading and 
uterine displacement. This finding suggests that prophylactic ephedrine may only be 
necessary in patients for elective Caesarean section.
In 1993 Rout et al. published a study that re-evaluated the efficacy of fluid preloading in 
spinal anaesthesia [32], They compared the haemodynamic effects of using a 
20ml per kg intravenous preload to using no preload in 140 patients for elective 
Caesarean section. They noted that there was a 16% (from 71% to 55%) reduction in
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the incidence of hypotension in the preload group. This difference, although statistically 
significant, was adjudged to be clinically insignificant.
In 1995, Jackson et al. performed a similar study on 60 women for elective Caesarean 
section, but used ephedrine on a prophylactic basis as an infusion [33], They compared 
the protective effect of a 1000ml fluid preload with that of a 200ml fluid preload. Both 
were administered 10 minutes before spinal anaesthesia was induced. They found that 
there was no significant difference in ephedrine requirements between the 2 groups, or in 
the incidence, severity or duration of hypotension. They advocated abandoning routine 
fluid preloading before regional anaesthesia.
1.4.3 Ephedrine - vasopressor of choice in pregnancy.
Schnider et al. published an animal study in 1968, which convincingly demonstrated the 
efficacy of ephedrine in treating hypotension [20], Using a pregnant ewe model, they 
monitored maternal and foetal blood pressures and arterial gases through a period of 
spinal hypotension and then through a recovery period initiated by ephedrine. They 
showed that when ephedrine was used to correct spinal hypotension, the foetal 
deterioration that had occurred was arrested and there was an improvement in foetal 
oxygenation, carbon dioxide elimination and fixed acid excretion.
In 1970, James et al. published another animal study in response to the studies by Greiss 
and by Schnider, whose findings on vasopressors in pregnant ewes conflicted [21], 
James et al. compared the effects on uterine blood flow of 3 different vasopressors: 
ephedrine, metaraminol and mephenteramine. As in previous studies, they used a 
pregnant ewe model. They found that ephedrine and mephenteramine did significantly 
increase uterine blood flow but never to more than 90% of pre spinal levels. They noted 
that higher doses caused increasing alpha-receptor stimulation and concluded that these 
vasopressors should be reserved for circumstances where other measures have failed.
In 1971, while comparing the effects of methoxamine and ephedrine in normotensive 
pregnant primates, Eng et al. unexpectedly found a significant decline in uterine blood
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flow after an intravenous ephedrine infusion was discontinued [34], The study confirmed 
that methoxamine caused relative foetal asphyxia by reducing uterine blood flow. They 
showed that ephedrine was relatively innocuous but expressed concern about potential 
foetal danger after discontinuation of the infusion.
Ralston et al. in 1974, attempted to provide a correlation between maternal blood 
pressure responses to various drugs and simultaneous changes in uterine blood flow and 
foetal acid-base status [28], They administered ephedrine, metaraminol, mephenteramine 
and methoxamine to 16 non-anaesthetised pregnant ewes. When maternal blood 
pressure was increased by 50%, uterine blood flow was unchanged with ephedrine and 
was reduced 20% with mephentermine, 45% with metaraminol and 62% with 
methoxamine. No significant change in foetal blood gas and acid-base variables was 
demonstrated. In their discussion they comment on the difference between their results 
and those of Eng et al. who had found ephedrine to be potentially harmful. It is their 
belief that the reduced uterine blood flow found by Eng after ephedrine infusion may 
have been due to a deterioration in their experimental animal preparation. They conclude 
that ephedrine is the vasopressor of choice in pregnancy.
1.4.4 Methods of ephedrine administration.
1.4.4.1 Intramuscular.
In 1976 Gutsche attempted to combine intramuscular ephedrine (that had been 
found to be relatively ineffective by Moya et al.), with fluid preloading and uterine 
displacement (that was found to be relatively ineffective by Clark et al.) [9], He 
performed a controlled study on 17 patients undergoing elective repeat Caesarean 
section under high subarachnoid block (T5-T1 sensory level). By using 50mg of 
ephedrine intramuscularly before induction, combined with an intravenous preload 
of 500mls of Ringer’s lactate solution and left lateral tilt, he was able to reduce the 
incidence o f hypotension from 100% in his control group to 25%. He showed no 
reactive hypertension and detected no evidence o f foetal gas exchange 
abnormalities. The study could be faulted for its use of a pharmacologically active
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drug, procaine, as its placebo and for its small sample size. To the candidate's 
knowledge, this study has not been repeated on a larger scale.
In 1979, Ward et al. used intramuscular ephedrine prior to epidural anaesthesia in 
an attempt to document the placental transfer of the drug, and to report on the 
foetal and neonatal effects of this transfer [29], They administered 25 or 50mg of 
ephedrine intramuscularly together with a fluid preload and left uterine 
displacement. Maternal cardiovascular status was found to be stable during the 
anaesthetic. In spite of finding foetal blood ephedrine levels to be approximately 
equal to maternal levels, they detected no measurable deleterious effects on foetal 
wellbeing or neonatal outcome.
Rolbin et al. evaluated the use of intramuscular ephedrine in elective Caesarean 
sections under epidural anaesthesia [1], They demonstrated an unacceptably high 
incidence of reactive hypertension (in their 50mg ephedrine group 75% of patients 
developed blood pressures greater than 20% above baseline and 50% developed 
blood pressures greater than 30% of baseline). They showed a lack of efficacy in 
preventing hypotension in a 25 and a 50mg group (incidences of hypotension in 
the control, 25 and 50mg groups were 12%, 12% and 14% respectively). As a 
result o f the detection of acid base abnormalities in arterial cord blood of the 50mg 
group, the study was terminated prematurely. No significantly low Apgar or 
neurobehavioural scores were detected. It should be noted that findings in epidural 
anaesthesia are not necessarily relevant to spinal anaesthesia - the physiologic 
changes, although essentially the same, differ markedly in their timing and severity.
Brizgys et al., in 1987, performed the first large scale prospective study on the 
incidence o f epidural hypotension since that of Casady in 1960 [35], They studied 
583 labouring and non-labouring women undergoing repeat and primary 
Caesarean section under epidural anaesthesia. They determined the incidence of 
maternal hypotension and its effects on neonatal clinical and acid-base status.
Their results indicated an overall incidence of maternal hypotension in epidural 
anaesthesia of 29%. In the early stages of the study intramuscular ephedrine (25 or 
50mg) was used but was discontinued when clinical observation showed no clear
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prophylactic benefit. Some benefit o f intramuscular ephedrine was evident in 
non-labouring mothers where the incidence of hypotension was reduced from 41% 
to 33%. Although findings in this study apply only to epidural anaesthesia, they do 
support the theory that prophylactic intramuscular ephedrine has a greater role in 
non-labouring mothers than in labouring mothers.
The only controlled study in the English literature in which 37,5mg of ephedrine 
was used intramuscularly to prevent spinal hypotension was performed in 1989 in 
a non-obstetric population (lower limb and lower abdominal procedures) by 
Hemingson et al [36], The study group was given 37,5mg of intramuscular 
ephedrine combined with an intravenous bolus of 12,5mg. Haemodynamic 
responses of this group were compared to those of a placebo group. They showed 
that in ASA III patients, there was a marked reduction in mean arterial pressure in 
the placebo group (30,8mmHg) which differed significantly from that in the 
ephedrine group (5,2mmHg). All ASA III patients in the placebo group had a 
reduction of mean arterial pressure of more than 20%. They concluded that it is 
appropriate to administer ephedrine in this manner prior to spinal anaesthesia 
particularly to patients o f ASA class III.
In 1992 Rout et al. designed a study to illustrate a specific concern that they had 
with prophylactic intramuscular ephedrine [2], The concern was the eventuality of 
giving intramuscular ephedrine and then failing to perform a spinal anaesthetic (the 
incidence o f spinal failure being of the order of 4%). They argued that if general 
anaesthesia was resorted to subsequently, the combination of vasopressor and 
general anaesthesia would result in deleterious effects to both the mother and the 
foetus.
They studied 30 parturients for elective Caesarean section under general 
anaesthesia. They compared the haemodynamic effects on the mother, and 
biochemical and clinical effects on the foetus; of a placebo, 25mg and 50mg of 
ephedrine intramuscularly. Their results showed that 50% of the 50mg group 
developed blood pressures of greater than 30% of control. They noted that 
neonatal acid-base status was impaired in the 50mg group as evidenced by an
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umbilical arterial pH of 7,16. In their view, the potential foetal risk in the event of 
a failed spinal was not justified by the cardiovascular responses; which they found 
to be inadequate in 50% of patients receiving 25mg, and excessive in 50% of 
patients receiving 50mg of ephedrine. On the basis of this conclusion, they state 
that the prophylactic administration o f intramuscular ephedrine prior to spinal 
anaesthesia for Caesarean section is not to he recommended.
The above statement forms the basis for the dissertation by this candidate.
1.4.4.2 Intravenous.
Kang et al. introduced the concept of using an intravenous infusion of ephedrine 
on a prophylactic basis in spinal anaesthesia [10], They titrated an infusion of 
0,01% ephedrine to maintain systolic blood pressure at 90-100% of baseline in 20 
patients. By doing this they were able to reduce the incidence of hypotension to 
10% (the lowest documented incidence in the literature). They noted a 
significantly higher incidence of nausea and vomiting in their control group who 
were treated with intravenous boluses of ephedrine when systolic blood pressure 
fell below 80% of baseline. They also noted in their control group that blood 
pressure did not return to baseline levels until approximately 6 minutes after 
‘rescue’ therapy was started.
In a similar theme and in the same year, Datta et al. demonstrated the virtue of 
giving intravenous boluses of ephedrine earlier than had been previously 
recommended [11]. A bolus of 10-30mg was given as soon as any fall from 
baseline blood pressure was detected. Combining this method with a large fluid 
preload (1500mls of Ringer’s lactate solution), they reduced the incidence and 
severity of hypotension significantly. As in the above study, they showed a marked 
reduction in the incidence o f nausea and vomiting in their study group. This 
reinforces the belief that nausea and vomiting are related to hypotension with 
consequent hypoxaemia of the medullary vomiting centres. Datta et al. also 
showed significantly better foetal acid-base status in subjects where systolic blood
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pressure remained above lOOmmHg compared to those where blood pressure 
dropped below lOOmmHg.
In 1984 Hollmen et al. used radioactive xenon to measure intervillous blood flow 
before and after epidural anaesthesia [37], They studied 18 patients, 9 of whom 
received a prophylactic intravenous bolus of 15mg ephedrine and 9 of whom did 
not. They were able to show that an intravenous bolus of ephedrine did not 
significantly alter intervillous blood flow. O f interest was the finding that in 88% 
of patients who had received the intravenous bolus, blood pressures had decreased 
to below pre-block and pre-ephedrine levels 20-25 min later. Based on this 
finding, they suggested that an intravenous infusion would be preferable to an 
intravenous bolus of ephedrine. In the candidate's opinion, the intramuscular route 
may also be of advantage in this regard.
In the same year, the same group of investigators, publishing under the name 
Jouppila, used the same radioactive xenon techniques to measure intervillous 
blood flow, this time under spinal anaesthesia [38], They demonstrated, in 9 
subjects, that the use of a preload of 1500 to 2000mls of Ringer’s lactate solution 
with the early administration of an ephedrine infusion can prevent a reduction in 
placental blood flow despite a moderate decrease in maternal blood pressure.
1.4.5 Editorials and review articles.
In 1989 an editorial on circulatory changes after epidural block for Caesarean section 
appeared in the Lancet [18]. The editorial concluded that since vasodilation is the 
common factor in all cases, the judicious use of vasopressors is the most effective and 
rapid way to reverse hypotension. It is observed that ephedrine is not only rapidly 
effective in restoring blood pressure but that it quickly reverses symptoms of vagal 
overactivity such as nausea and vomiting. Intravenous fluids are described as unreliable 
as a prophylactic measure and too slow to be of use in treatment.
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McCrae and Wildsmith reviewed the prevention and treatment of hypotension during 
central neural blockade in the British Journal of Anaesthesia in 1993 [17], Summarising 
the literature on fluid preloading they state that studies are contradictory even in the 
incidence of hypotension in the control groups. They comment that infusions o f large 
volumes of fluid have been shown to overload the right side of the heart and that 
obstetrical patients are at increased risk for pulmonary oedema because interstitial lung 
water is increased during the puerperium. They suggest that a more physiological 
approach to the treatment of hypotension induced by sympathetic block is to counteract 
it as it occurs by using sympathomimetic drugs. As regards intramuscular ephedrine, 
McCrae and Wildsmith were influenced largely by Rolbin’s study that was done in 
epidural anaesthesia. They describe the modality as not reliably preventing hypotension 
and being associated with unacceptable hypertension. They recommend awaiting the 
onset of hypotension and then treating it with intravenous ephedrine.
In 1995, Morgan reviewed spinal anaesthesia in obstetrics in the Canadian Journal of 
Anaesthesia [3], She took cognisance of Rout’s finding that preloading did not eliminate 
the hypotension associated with spinal anaesthesia. However, she quotes a letter by 
Bassell and Marx that points out the salutary effect of volume on uteroplacental blood 
flow and cautions against not preloading patients [39], Morgan was also guided by the 
Rolbin study in her approach to intramuscular ephedrine and also advocated awaiting the 
onset of hypotension and then treating it immediately with fluid and vasopressors.
1.4.6 Summary.
For the sake of clarity the general trends in the literature are summarised as follows:
• Spinal anaesthesia in obstetrics becomes popular in the 1940’s
• In the 1950’s, prophylactic intramuscular vasopressors are widely used in 
managing hypotension
• In the 1960’s prophylactic vasopressors are brought into disrepute by reports 
of hypertensive complications and concerns about the effect of vasopressors 
on uteroplacental blood flow
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• In the 1960’s and early 1970’s animal trials show conclusively that direct 
acting alpha stimulants do reduce uteroplacental blood flow. Ephedrine is 
found to be safe.
• Fluid preloading becomes the mainstay o f hypotension prophylaxis after 
studies in the late 1960’s demonstrate the efficacy thereof.
• In 1976, a small controlled study by Gutsche in spinal anaesthesia found 
prophylactic intramuscular ephedrine to be safe and to reduce the incidence of 
hypotension to 25%.
• During the 1970’s and 1980’s epidural anaesthesia is favoured over spinal 
anaesthesia for Caesarean section.
• In 1982, intramuscular ephedrine is evaluated in epidural anaesthesia where it 
is found to be ineffective and to cause hypertension and foetal acidosis.
• In the 1990’s spinal anaesthesia enjoys a resurgence in popularity.
• In the 1990’s, 2 studies demonstrate the inadequate protective effect of fluid 
preloading.
• In 1996, vasopressors, particularly ephedrine, continue to play an important 
role in the management of spinal hypotension but the manner in which they are 
used remains contentious.
It is the candidate's impression that the apparent lack of consistency of results in the 
literature may be due to inadequate standardisation. Studies are compared which differ 
in type of anaesthesia (spinal or epidural), type of patient (differing size; labouring or 
non-labouring), and height of block. It may be useful therefore, to reproduce and 
validate previous research. This study will repeat research done by Gutsche in 1976 but 
will differ in using a larger sample size, a more appropriate placebo and a lower dose of 
ephedrine [9],
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1.5 ALMS OF THE STUDY
1.5.1 Statement of the Problem.
There are various aspects regarding the use of prophylactic intramuscular ephedrine that 
require clarification.
• Is a bolus dose of 37,5mg o f intramuscular ephedrine potentially harmful:
- to the mother by causing hypertension and tachycardia?
- to the foetus by compromising placental gas exchange?
• Is a bolus dose of 37,5mg o f intramuscular ephedrine effective in preventing 
hypotension caused by spinal anaesthesia?
1.5.2 Null Hypotheses.
• An intramuscular bolus of 37,5mg of ephedrine causes no significant maternal 
hypertension and tachycardia.
• An intramuscular bolus of 37,5mg of ephedrine causes no significant foetal 
acidosis.
• An intramuscular bolus of 37,5mg of ephedrine does not reduce the incidence 
or severity of hypotension following spinal anaesthesia.
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CHAPTER 2
MATERIALS AND METHODS
2.1 STUDY POPULATION AND PATIENT SELECTION.
Forty (40) patients of ASA physical status I and II, presenting for elective Caesarean 
section at Baragwanath Hospital, were entered into the study. Institutional ethical 
committee approval was obtained and all the patients gave informed consent (appendix 
B). The study was also approved by the Pharmaceutics and Therapeutics committee of 
Baragwanath Hospital. All patients were given the choice of withdrawing from the study 
at any time (appendix B). All consenting patients were entered into the study. Exclusion 
criteria included the following-
• obesity which resulted in an inability to palpate lumbar spines
• hypertension (blood pressure greater than 150/90)
• conventional contraindications to spinal anaesthesia i.e.coagulopathy, sepsis, 
lack of consent, hypovolaemia (clinically assessed).
The patients were admitted to the hospital at least one day prior to surgery. The 
candidate performed a pre-operative assessment on all the patients on the morning of 
surgery, and at this point asked the patients whether they would consent to enter the 
study. The patients were presented with an information sheet (appendix A) and a 
consent form (appendix B) and were asked to peruse them. Written consent was then 
obtained from those who agreed to enter the study.
All of the patients entered into the study were randomly allocated to one of two groups. 
Randomisation was achieved by placing slips of paper labelled as follows in sealed 
envelopes:-
• Ephedrine
• Normal saline
Twenty (20) of each of these slips of paper were placed in unmarked individual 
envelopes resulting in a total of forty (40) envelopes. The envelopes were shuffled into 
random order and placed in a box. As each patient arrived in the operating theatre an
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assistant opened an envelope which indicated to him which syringe, either ephedrine or 
normal saline, he should prepare for the candidate. The candidate was unaware of which 
of the two solutions he would administer as an intramuscular injection.
Spinal anaesthesia would then be administered in the manner described below (see 
Method 2.3).
2.2 MATERIALS.
2.2.1 Monitoring equipment
• A Criticon dinamap (Johnson and Johnson, South Africa) was used to measure 
systolic, diastolic, mean blood pressure and pulse rate non invasively.
• An ECG machine provided continuous ECG monitoring (Diascope 2,
S & W Medico Teknik A/S, Denmark).
• A pulse oximeter (Ohmeda, Louisville U.S.A.) monitored oxygen saturation 
continuously.
2.2.2 Subarachnoid injection
• 25 G Spinocan Quinke needles for administering the spinal anaesthetic.
• local anaesthetic solution was constituted as follows:
- 4,5mls bupivacaine 0,5% was admixed with 0,5ml o f 50% 
dextrose water to achieve 5mls of 0,45% hyperbaric bupivacaine.
- 2,5mls (1 l,25mg bupivacaine) of this solution was injected 
into the subarachnoid space.
2.2.3 Umbilical cord blood sampling
• 2ml heparinised syringe
• Ilex blood gas analyser IL 1640 (Milano, Italy)
2.2.4 Other intravenous medications
• syntocinon 20 units
• cefoxitin lgm
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2.3 METHODS
All patients were starved and prepared as for Caesarean section under general 
anaesthesia. They were premedicated with an oral dose of 30mls of 0,3 molar sodium 
citrate.
On entering the operating theatre the patient was placed in the recovery room area, an 
intravenous cannula (18 G) placed in a left forearm vein and the monitoring equipment 
described above attached. The cuff o f the dinamap was placed around the right arm and 
blood pressure and heart rate monitored at 3 minute intervals to obtain baseline 
readings. The mean of three values was used provided that the systolic pressure did not 
vary by more than 10%. Following baseline readings, patients received an intravenous 
infusion of 500mls of Ringer’s lactate solution over a period of approximately 15 
minutes.
Patients were then moved into the theatre and placed on the operating table in a 
conventional sitting position. At this point patients received an intramuscular injection 
into the left deltoid of either normal saline or ephedrine. Following this injection the 
values of the blood pressure and the pulse rate were manually recorded at one minute 
intervals for a period of 30 minutes and thereafter at 5 minute intervals for 40 minutes 
and then at 10 minute intervals for 20 minutes (appendix C).
After local infiltration of the skin with 2mls of 2% Iignocaine, spinal anaesthesia was 
administered by the candidate under aseptic conditions - 2,5mls of 0,45% hypertonic 
bupivacaine was injected through a 25 G Quinke needle inserted at the L3 L4 interspace.
After injection of the anaesthetic solution, the patient was placed in a supine position 
and tilted 15 degrees to the left. Oxygen at 8 litres per minute was administered via a 
plastic disposable face mask from the time of induction of anaesthesia until termination 
of surgery. The spread of the sensory blockade was tested with an ice cube 15 minutes 
after subarachnoid injection.
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If maternal hypotension (defined as a fall in systolic blood pressure of more than 30% or 
to below lOOmmHg) occurred, ephedrine was given intravenously, 5mg doses every 
minute, until the systolic arterial pressure rose to at least lOOmmHg. The rate of 
intravenous fluid infusion was also increased over that period.
The blood loss and total volume of intravenous fluid administered were assessed and 
recorded by the assistant. In addition to the physiological parameters recorded, any 
complications during the procedure were noted. Such complications included nausea, 
vomiting and pain.
Times o f ephedrine injection, spinal injection, skin incision, uterine incision, delivery of 
the baby and conclusion of surgery were recorded by an assistant. The time from uterine 
incision to umbilical cord cross clamp was recorded by the candidate with a stop watch 
(appendix D).
The foetus was assessed by Apgar scoring at 1 and 5 minute intervals by the assistant.
At delivery, a sample of umbilical venous blood from a doubly clamped segment of 
umbilical cord was collected. Blood gases were immediately determined with an Ilex 
blood gas analyser (appendix E).
At the conclusion of surgery, patients were transferred to the recovery room for 
continued monitoring and recording of haemodynamic parameters. If maternal 
hypotension occurred, intravenous ephedrine boluses were given in the same manner as 
above.
Ninety (90) minutes after the intramuscular injection, monitoring was discontinued and 
the patient discharged to the ward.
Data was recorded manually on the data sheets (appendix C).
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2.4 STATISTICAL ANALYSIS
The following statistical tests were performed as appropriate using the GraphPad Instat 
programme, version 2,05A (GraphPad Software Inc., San Diego, California, USA)
2.4.1 Fisher’s Exact Probability Test
2.4.2 Student’s t-test for unpaired samples
Any P value of less than 0,05 was considered statistically significant. The results and the 
statistical tests performed to analyse the results are discussed in Chapter 3.
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CHAPTER 3
RESULTS
As discussed in Chapter 2, twenty patients in the study group received an intramuscular 
injection of 37,5mg of ephedrine and twenty patients in the control group received an 
intramuscular injection of normal saline prior to spinal anaesthesia.
3.1 DEMOGRAPHIC DATA
Table 3.1
The mean values for age, weight, height and delivery time and the mode value for level 
of sensory block for the two groups. Delivery time was defined as the time interval from 
uterine incision to clamping of the umbilical cord.
A G E -
years
Y V E I G H T -
kg
H E I G H T -
cm
D E L IV E R Y
T IM E -
seconds
H E I G H T  O F
S E N S O R Y
B L O C K
C O N T R O L
G R O U P
30
(sd 5,5)
77
(sd 14,3)
161
(sd 6,2)
92
(sd 30)
T2
S T U D Y
G R O U P
28
(sd 4,5)
82
(sd 13,3)
164
(sd 4,7)
86
(sd 31)
T2
t 1.26 1.14 1.72 0.62
P 0.21 0.26 0.09 0.53
The two groups (Table 3.1) were compared in respect of age, weight, height and 
delivery time by means of the Student’s t-test. No statistically significant differences 
were found between the groups.
The ASA physical status of the two groups was as follows-
• Control group: 18 subject ASA I and 2 subjects ASA II
• Study group: 20 subjects ASA I
The mean baseline systolic blood pressures for the two groups were as follows-
• Control group: 125 (sd 12,4)
• Study group: 123 (sd 13,2)
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3.2 HYPERTENSION - THE INCIDENCE AND SEVERITY.
Tabic 3.2
The number of patients in each group in whom reactive hypertension occurred. Reactive 
hypertension was defined as an increase in systolic blood pressure o f more than 30% 
from baseline after ephedrine was administered.
CONTROL GROUP STUDY GROUP
Hypertension 4 6
No hypertension 16 14
The prevalence of hypertension was compared between the two groups by means of 
Fisher’s Exact Probability Test. No statistically significant difference was found. 
The P value was 0,716.
Table 3.3
The number of patients in each group in whom persistent hypertension occurred. 
Persistent hypertension was defined as an increase in systolic blood pressure of greater 
than 30% from baseline occurring in the post-operative period.
CONTROL GROUP STUDY GROUP
Persistent hypertension 0 1
No persistent 
hypertension
20 19
The two groups were compared in respect o f persistent hypertension by means of 
Fisher’s Exact Probability Test. No statistically significant difference was found. 
The P value was 1,0.
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Table 3.4
The raw data and mean values for the highest recorded blood pressures occurring in 
patients from the two groups.
CO NTROL GROUP STUDY GROUP
1 166 150
2 161 176
3 155 141
4 150 139
5 171 156
6 133 158
7 142 160
8 156 150
9 166 148
10 127 136
11 139 175
12 136 148
13 147 161
14 162 157
15 146 157
16 142 149
17 147 137
18 150 143
19 160 152
20 141 163
Mean 150 153 1
Standard deviation 12 11,2
The raw data, mean and standard deviation are listed in Table 3.4 above and shown as a 
bar chart for emphasis in Figure 3.1.
The two groups were compared in respect of the above by means of the Student’s t-test. 
No statistically significant difference was found.
The P value was 0,4188 (t value o f 0,82).
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FIGURE 3.1
A bar chart of the mean values o f the highest systolic blood pressures for the two 
groups.
Control group
Study group
Table 3.5
The mean systolic blood pressures of both groups immediately before subarachnoid 
injection and immediately following delivery.
Blood pressure
pre-spinal injection
Blood pressure
post-delivery
CONTROL GROUP 133mmHg (sd 14,9) 122mmHg (sd 14,6)
STUDY GROUP 140mmHg (sd 9,8) 127mmHg (sd 11,6)
The two groups were compared in respect of the above by means of the Student’s t-test. 
No statistically significant differences were found. The P values were as follows -
• blood pressure pre-spinal injection P=0,087 (t value of 1,76)
• blood pressure post-delivery P=0,277 (t value of 1,20).
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3.3 TACHYCARDIA - INCIDENCE AND SEVERITY
Table 3.6
The number of patients in each group in whom tachycardia occurred. Tachycardia was 
defined as a heart rate of greater than 120 beats per minute.
CONTROL GROUP STUDY GROUP
Tachycardia 13 14
No tachycardia 7 6
The two groups were compared in respect of the prevalence of tachycardia by means of 
Fisher’s Exact Probability Test. No statistically significant difference was found.
The P value was 1,00.
Table 3.7
The means of all heart rates recorded in the first 30 minutes and the means of the highest 
heart rates recorded.
Mean pulse rate - first 
30 minutes
Mean highest pulse rate
CONTROL GROUP 92 beats per minute 
(sd 13,8)
123 beats per minute 
(sd 20,5)
STUDY GROUP 96 beats per minute 
(sd 16,6)
130 beats per minute 
(sd 21,4)
The two groups were compared in respect of the above by means of the Student’s t-test. 
No statistically significant differences were found. The P values were as follows-
• mean pulse rate P=0,413 (t value of 0,83)
• mean of highest pulse rates P=0,293 (t value of 1,07).
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3.4 HYPOTENSION - INCIDENCE AND SEVERITY.
In the analysis of the data with regard to hypotension two subgroups evolved in the 
study group. Ten of the twenty subjects in the study group had their spinal anaesthetic 
induced approximately 5 minutes (range 5-8 minutes), after ephedrine administration. In 
the other 10 subjects an interval of approximately 10 minutes (range 9-14 minutes) 
occurred between ephedrine injection and induction of anaesthesia. Thus the study 
group divides into ‘5 minute’ and ‘10 minute’ subgroups.
Table 3.8
The number of patients in each group in whom hypotension occurred. Hypotension was 
defined as a decrease in systolic blood pressure below lOOmmHg or by more than 30% 
from baseline blood pressure
CONTROL
GROUP
STUDY
GROUP
STUDY
GROUP
‘5 minute’
STUDY
GROUP
‘10 minute’
Hypotension 16 10 7 3
No
hypotension
4 10 3 7
The two groups were compared in respect of the above by means of Fisher’s Exact 
Probability Test.
• No statistical difference was found between the control group and the study 
group. The P value was 0,0958.
• No statistical difference was found between the control group and the 
‘5 minute’ subgroup. The P value was 0,6573.
• A statistically significant difference was found between the control group and 
the ‘JO minute ’ subgroup. The P value was 0,0147.
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Table 3.9
The number of patients in whom delayed hypotension occurred. Delayed hypotension 
was defined as hypotension occurring more than 30 minutes after subarachnoid 
injection.
CONTROL GROUP STUDY GROUP
Delayed hypotension 10 2
No delayed hypotension 10 18
The two groups were compared in respect of the above by means o f Fisher’s Exact 
Probability Test. A statistically significant difference was found.
The P value was 0,0138.
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Table 3.10
The raw data and mean values for the lowest recorded systolic blood pressures 
occurring in patients from the two groups.
CONTROL GROUP STUDY GROUP
1 64 101
2 121 95
3 94 100
4 93 113
5 82 100
6 109 103
7 106 122
8 98 117
9 88 114
10 91 83
11 100 112
12 83 107
13 76 110
14 83 88
15 92 90
16 76 80
17 92 91
18 96 93
19 82 83
20 49 82
Mean 89 99
Standard deviation 15.8 12.8
The raw data, mean and standard deviations are listed in Table 3.10 and shown as a bar 
chart for emphasis in Figures 3.2 and 3.3.
The two groups were compared in respect of the above by means of the Student’s t-test. 
A statistically significant difference was found. The P value was 0,034 (t value of 
2,199).
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Figure 3.2
A bar chart of the mean values of the lowest systolic blood pressures for the control and 
study groups.
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Figure 3.3
A bar chart o f the mean values o f the lowest systolic blood pressures for the control 
group and the two study subgroups.
The values for the mean lowest systolic blood pressure for the two subgroups are as 
follows -
‘5 minute’ subgroup: 94 (sd 11,9)
‘10 minute’ subgroup: 107 (sd 13,3)
The groups were compared in respect of the above by means of the Student’s t-test.
• No statistically significant difference was found between the control group and the 
‘5 minute’ subgroup. The P value was 0,2654 (t value of 1,13).
• A statistically significant difference was found between the control group and the 
'10 minute ’ subgroup. The P value was 0,0007 (t value of 3,68).
• A statistically significant difference was found between the ‘5 minute ’ and the 
‘10 minute ’ subgroups. The P value was 0,0476 (t value o f 2,13).
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3.5 FOETAL CONDITION
3.5.1 Umbilical venous blood gas and acid base analysis
Data sets were not complete in all cases. Two subjects from the study group were 
removed from analysis because of errors arising from malfunction of the blood gas 
analyser.
Table 3.11
The values for umbilical venous pH, pC02, p02 and HC03 for the two groups and the 
values for pH for the two subgroups.
Umbilical
venous
CONTROL
GROUP
STUDY
GROUP
5 minute 
subgroup
10 minute 
subgroup
PH 7,35 (sd 0,05) 7,31 (sd 0,06) 7,30(sd 0,03) 7,33(sd 0,02)
pC02 38,8 (sd 5,1) 40,25(sd 5,7)
p02 23,8 (sd 7,8) 25,5(sd 6,3)
HC03 21,2 (sd 2,6) 20,05(sd 2,2)
The groups were compared in respect o f pH by means of the Student’s t-test.
• A statistically significant difference was found between the control group and 
the study group. The pH in the study group was lower. The P value was 
0,0424 (t value of 2,11).
• A statistically significant difference was found between the control group and 
the ‘5 minute’ subgroup. The pH in the ‘5 minute’ subgroup was lower.
The P value was 0,0091 (t value of 2,8).
• No statistically significant difference was found between the control group and 
the ‘10 minute’ subgroup. The P value was 0,3046 (t value of 1,05).
The groups were compared in respect of the other blood gas variables
(pC02, p02 and HCO3) by means of the Student’s t-test. No statistically significant
differences were found. The P values were as follows-
• pC02, P=0,4260 (t value of 0,81)
• p02, P=0,4860 (t value of 0,70)
• HCO3, P=0,1521 (t value of 1,46)
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3.5.2. Apgar scores
The mean Apgar scores for the two groups at 1 minute and 5 minutes are as follows -
• Control Group 9 + 1 0
• Study Group 9 +1 0 .
3.6 COMPLICATIONS
There was no significant difference between the groups in the incidence of nausea, 
vomiting and pain. Six patients, three in each group, complained of nausea 
intraoperatively. Transient hypotension had occurred in 5 of those patients. No patient 
complained of discomfort or pain intraoperatively.
The average blood loss per patient was estimated at 500mls for both groups.
The average volume of intravenous Ringer’s lactate solution used per patient was 
1300mls for both groups.
3.7 NULL HYPOTHESES -CONCLUSIONS.
• The Null hypothesis which stated that an intramuscular bolus of 37,5mg of ephedrine 
causes no significant maternal hypertension and tachycardia, is supported.
• The Null hypothesis which stated that a intramuscular bolus of 37,5mg of ephedrine 
causes no significant foetal acidosis is supported for the subgroup in which a 10 
minute interval between ephedrine injection and spinal induction occurred.
• The Null hypothesis which stated that an intramuscular bolus of 37,5mg of ephedrine 
does not reduce the incidence or severity of hypotension following spinal anaesthesia 
is rejected for the subgroup in which a 10 minute interval between ephedrine 
injection and spinal induction occurred.
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CHAPTER 4
DISCUSSION AND CONCLUSIONS.
4.1 GENERAL REMARKS.
This study was undertaken to test the validity of the statement ‘the prophylactic 
administration of intramuscular ephedrine prior to spinal anaesthesia is not to be 
recommended’ [2],
The safety and efficacy of intramuscular ephedrine in the context of spinal anaesthesia in 
obstetrics have not been well documented. To the candidate’s knowledge, only one 
controlled study has been published. As discussed in Chapter 1, that study, by Gutsche, 
was small (n=17) and could be faulted for using a pharmacologically active agent 
(procaine, with a known vasodilator effect) as placebo [9], In spite of this, on the basis 
of that study, the technique continues to be recommended by contemporary text books 
[12]. Doses o f 25mg or 50mg are suggested. No specific reference is made to the 
interval between ephedrine administration and the induction of spinal anaesthesia.
This is the first study to compare the efficacy and safety of prophylactic intramuscular 
ephedrine in spinal anaesthesia for Caesarean section with a true placebo. It is the first 
study in obstetrical anaesthesia to use a dose of 37,5mg of ephedrine intramuscularly 
and it is also the first study to comment on the influence of the time interval between 
ephedrine administration and spinal induction on the efficacy and safety of the technique.
The two groups in the study were well matched as to demographic criteria. All the 
subjects presented for the same surgical procedure in the same hospital but were 
operated on by different surgeons. All of the spinal inductions were carried out by the 
candidate. Interfering variables were reduced to a minimum. The average sensory level, 
assessed 20 minutes after induction of anaesthesia, was T2 (Gutsche recommends a 
sensory blockade to the level of T2 to avoid the visceral discomfort associated with 
traction on the peritoneum) [40],
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4.2 HYPERTENSION.
The major concern regarding intramuscular ephedrine has been its association with 
persistent reactive hypertension. This study was designed to address this concern. 
Reactive hypertension related to vasopressor use was first documented in 1962 after a 
cerebrovascular accident was causally linked to the administration of a combination of 
an intramuscular alpha stimulant and an ergot alkaloid [6], More recently, in 1982, an 
unacceptable level of hypertension was found when intramuscular ephedrine was used in 
epidural anaesthesia (a 75% incidence o f significant hypertension associated with 50mg 
of intramuscular ephedrine) [1], Hypertension was defined as an increase in systolic 
blood pressure o f greater than 30% above baseline. In 1992 Rout et al. demonstrated 
reactive hypertension in patients given intramuscular ephedrine prior to general 
anaesthesia [2], In their study 90% of patients who received 50mg of ephedrine 
increased their blood pressures by more than 20%.
This study in spinal anaesthesia detected a substantially lower incidence of hypertension 
than the above studies did. It found no increase in either the incidence or the severity of 
hypertension (defined as 30% above baseline) in the study group compared to the 
control group. The incidence of hypertension in the study group was only 30% which 
was not significantly higher than that in the control group (20%) (P=0,716). No other 
evidence of significant hypertension was found. The mean highest blood pressure in the 
study group was 153mmHg (sd 11,2) compared to 150mmHg (sd 12) in the control 
group (not significant P=0,419). There was no difference between the groups in mean 
blood pressure taken immediately before induction of spinal anaesthesia or immediately 
after delivery o f the baby.
No significant incidence of persistent post-operative hypertension was detected in the 
study group. Only one patient in that group was found to be hypertensive 
post-operatively. This was in contrast with the finding in the above mentioned study in 
epidural anaesthesia, of an incidence of persistent hypertension of 66% [1], 
Haemodynamic changes caused by ephedrine in epidural or general anaesthesia cannot 
be equated with those in spinal anaesthesia.
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4.3 TACHYCARDIA.
The study detected a high incidence of tachycardia in both the control group and the 
study group. Tachycardia was defined, for the purposes of the study, as a heart rate of 
greater than 120 beats per minute. The incidence of tachycardia in the study group was 
70% which was however, not significantly higher than that in the control group (65%) 
(P=1,00).
There was no evidence that the intramuscular technique resulted in significantly higher 
pulse rates than the intravenous bolus technique. The mean of the highest pulse rates in 
the study group was 130 (sd 21,4) beats per minute which was not significantly higher 
than that of the control group which was 123 (sd 20,5) beats per minute (P=0,293). The 
mean of all pulse rates in the first 30 minutes was 96 (sd 16,6) beats per minute for the 
study group compared to 92 (sd 13,8) beats per minute for the control group (not 
significant P=0,413).
4.4 HYPOTENSION.
With regard to efficacy in preventing hypotension, Gutsche had previously demonstrated 
a reduction in the incidence o f hypotension from 100% to 25% with 50mg of 
intramuscular ephedrine [9]. The definition of a hypotensive episode, in this study, 
coincides with that of the majority of previous studies i.e. a decrease in systolic blood 
pressure of greater than 30% from baseline or a decrease in systolic blood pressure to 
below lOOmmHg.
In this study the incidence of hypotension in the study group (50%) was less but not 
significantly less than that in the control group (80%) (P=0,0958). However, differences 
between the groups in terms of severity of hypotension did achieve statistical 
significance. The mean lowest systolic blood pressure in the study group was 99mmHg 
(sd 12,8) which differed significantly from that of the control group which was 89mmHg 
(sd 15,8) (P=0,034). The mean systolic blood pressure in the study group dropped by
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19,5% (from 123mmHg to 99mmHg), whereas that of the control group dropped by 
28,8% (from 125mmHg to 89mmHg).
The most notable effect of intramuscular ephedrine was demonstrated when a ‘10 
minute’ subgroup, as defined by the interval between ephedrine administration and 
subarachnoid injection, was separated from a ‘5 minute’ subgroup. The cardiovascular 
stability of subjects in the ‘10 minute’ subgroup was noteworthy. The incidence of 
hypotension was only 30%. The mean lowest systolic blood pressure was 107mmHg (sd 
13,3) reflecting a reduction in mean systolic blood pressure of only 13% (from 
123mmHg to 107mmHg) i.e. significantly less frequent (P=0,0147) and less severe 
(P=0,0007) hypotension than was found in the control group.
Considerable cardiovascular instability was evident in the ‘5 minute’ subgroup. The 
incidence of hypotension was 70% which was not significantly different to that in the 
control group (80%) (P=0,6573). The mean lowest blood pressure was 94mmHg 
(sd 11,9) (i.e. a decrease o f 24%), which also was not significantly different to that in 
the control group (P=0,2654). One patient in the ‘5 minute’ subgroup required 15mg of 
intravenous ‘rescue’ ephedrine after a precipitous fall in blood pressure. She developed a 
severe tachycardia (170 beats per minute) and although her baby was clinically healthy, 
analysis o f umbilical venous blood revealed evidence of possible transient asphyxia 
(pH 7,1).
These findings confirm the efficacy of 37,5mg of intramuscular ephedrine but mandate a 
minimum time interval between ephedrine injection and spinal induction of 10 minutes.
Another important finding was that o f a low incidence of post-operative or delayed 
hypotension in subjects in the study group. Delayed hypotension was defined for the 
purposes of the study as hypotension occurring more that 30 minutes after induction of 
spinal anaesthesia. The incidence of delayed hypotension (requiring intravenous 
ephedrine boluses) was 50% in the control group compared to only 10% in the study 
group (P=0,0138) i.e. intramuscular ephedrine provides more sustained cardiovascular 
support than intravenous ephedrine. Intramuscular ephedrine may be particularly
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advantageous where post-operative monitoring may not be reliable and where 
post-operative hypotension may go undetected.
4.5 FOETAL WELLBEING AND NEONATAL OUTCOME.
As discussed in the introduction, intramuscular ephedrine has been associated with 
abnormalities in foetal gas exchange [1,2]. It is well known that the uterine vascular bed 
has a high adrenoreceptor density which renders uteroplacental blood flow potentially 
vulnerable to vasoconstriction induced by alpha-adrenergic agonists. Ephedrine, 
although causing less vasoconstriction than pure alpha-agonists, does have a dose 
related alpha effect.
Both Rolbin and Rout have demonstrated dose related deterioration in foetal gas 
exchange with intramuscular ephedrine used in an epidural and general anaesthetic 
context respectively. Rolbin et al. showed an umbilical venous pH of 7,31 in their 50mg 
intramuscular ephedrine group and Rout et al., a pH of 7,24. Their patients’ umbilical 
artery pHs were 7,18 and 7,16 respectively. Apgar scores were normal in both studies 
and neurobehavioural scores were normal in the Rolbin study. In contrast, neither Ward 
nor Gutsche found any adverse effect on foetal gas exchange associated with 50mg 
intramuscular ephedrine in epidural or spinal anaesthesia [9,29],
This study did detect a decrease in umbilical venous pH in the intramuscular ephedrine 
group, which may have been dose related. Since the primary focus of this study was on 
maternal haemodynamics, only umbilical venous blood was collected so that gross 
biochemical derangement in the foetus could be excluded. The mean umbilical venous 
pH of subjects in the control group was 7,35 (sd 0,052) and that of subjects in the study 
group 7,31 (sd 0,065) (significant P=0,0424).
Of interest, however, was an analysis of the data in terms of the ‘5 and 10 minute’ 
subgroups mentioned previously. The mean umbilical vein pH of subjects in the ‘10 
minute’ subgroup of the study group was 7,33 (sd 0,02) which is not significantly lower 
than that of the control group (7,35 sd 0,052) (P=0,3046). The mean umbilical vein pH
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of subjects in the ‘5 minute’ subgroup was 7,30 (sd 0,03) which was significantly lower 
than that of the control group (7,35 sd 0,052) (P=0,0091) i.e. the decrease in pH may be 
a dose related phenomenon as subjects in the ‘5 minute’ subgroup received considerably 
more intravenous ‘rescue’ ephedrine (130mg), than subjects in the ‘10 minute’ group 
(20mg). Although subjects in the control group were given relatively large amounts of 
intravenous ‘rescue’ ephedrine, the total dose received (385mg) was substantially less 
than that in the study group (900mg, of which only 150mg was given as ‘rescue’ 
treatment).
There were no differences between the groups in any of the other cord blood gas 
variables i.e. p02, pCCh, HCO3 . There were no detectable clinical consequences of the 
lower venous pH values in the study group i.e. Apgar scores were all above 8. It should 
be noted that although there were statistically significant differences between the groups, 
all pH values were within normal reference ranges [41].
The above findings reinforce the need for a minimum time interval of 10 minutes 
between ephedrine injection and spinal induction, and the use of the lowest effective 
dose of ephedrine possible. Data from this study suggests that 37,5mg is an adequate 
maximum dose for intramuscular administration (to replace the current recommended 
maximum dose o f 50mg).
4.6 CONCLUSIONS.
Based on the findings of this study, the candidate recommends the following guidelines 
for the use of prophylactic intramuscular ephedrine:
• 37,5mg should be considered the maximum dose
• the time interval between intramuscular ephedrine administration and induction 
of spinal anaesthesia should never be less than 10 minutes
• for optimal effect, the technique should be combined with fluid preloading and 
left lateral tilt
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• the technique should be used only by practitioners experienced in spinal 
anaesthesia and only in patients where no difficulty in administering the spinal 
is anticipated
• the technique has application mainly in non-labouring patients.
In conclusion, the findings of this study suggest that ephedrine administered in the above 
manner is effective in preventing hypotension and is safe from a maternal haemodynamic 
point of view. As regards the foetus, the question as to whether transient exposure to 
ephedrine is more or less dangerous than transient hypotension was not specifically 
addressed by this study. Although no deleterious effect to the foetus was detected when 
ephedrine was given 10 minutes prior to induction, this question remains a subject for 
future research in which more specific parameters o f foetal response could be used.
Although it is self evident that intramuscular administration provides less predictable 
plasma levels of ephedrine than intravenous, the study showed that levels achieved 
provide safe and effective cardiovascular support. A future pharmacokinetic study of 
intramuscular ephedrine could reinforce the candidate’s clinical observations. In a busy 
operating theatre environment of limited resources such as the one at Baragwanath 
Hospital, the intramuscular administration o f ephedrine has specific utility in its economy 
of effort and equipment and offers the considerable advantage of sustaining blood 
pressure well into the post-operative period.
The recommendation of Rout et al. in 1992 was that intramuscular ephedrine be avoided 
in obstetrical spinal anaesthesia [2], As discussed in the introduction, the evidence on 
which this recommendation is based is not, in the candidate’s view, convincing. This is a 
time honoured and effective technique which should not be discarded by the anaesthesia 
community without good reason.
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APPENDIX A
SUBJECT INFORMATION SHEET
BACKGROUND:
We intend using spinal anaesthesia for your Caesarian Section. Spinal 
anaesthesia is very popular because of it's safety and because it allows 
the mother to be aware of her babies' birth.Spinal anaesthesia is given by a 
simple injection in your back.
A common problem with spinal anaesthesia is hypotension (low blood 
pressure). We treat hypotension by giving fluids by means of a drip and by 
using a drug named ephedrine.
We are asking you to participate in a research study which will help us to 
learn whether, if the ephedrine is given before the spinal is done, we can 
prevent the problem of hypotension (low blood pressure).
PROCEDURE:
You will have your blood pressure checked on arrival in theatre. You will 
then be given an injection of either ephedrine or an inactive substance 
named normal saline. ( For the purposes of the research, neither you nor the 
supervising doctor will know which injection you have been given.) Shortly 
thereafter the spinal anaesthetic will be given and the Caesarian Section 
performed. You will have your blood pressure repeatedly checked before, 
during and after the Caesarian Section.
POSSIBLE RISKS:
- If you receive the ephedrine injection you may develop brief hypertension 
(high blood pressure) which has not been shown by previous use of this 
drug to be dangerous and which, if neccesary , may be treated.
- If you receive the normal saline injection you may develop brief 
hypotension (low blood pressure) which we will treat with ephedrine given 
into the drip.
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BENEFITS:
- all patients will benefit by receiving the best anaesthetic technique 
available for Caesarian Section.
- if you receive the ephedrine injection before the spinal you may experience 
less blood pressure instability.
- your participation will help to give our mothers better care in the future.
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APPENDIX B
CONSENT TO PARTICIPATE IN EPHEDRINE TRIAL
PATIENT:
I agree to take part in the trial.
I have been given an explanation of the nature and purposes and possible 
hazards of the trial.
I confirm that I have informed the supervising doctor of any illness I may 
suffer from or of any drugs that I may be using.
I agree to co-operate fully with the supervising doctor and will report any 
unusual symptoms to him.
I am free to refuse to participate or to withdraw my consent and discontinue 
my participation in the study at any time and receive the normal treatment 
nccccssary.
SUPERVISING DOCTOR:
I confirm that I have explained the nature, purpose and possible hazards of the 
trial to the patient.
NAME:
SIGNATURE:
DATE:
NAME:
/I)
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EPHEDRINE TRIAL - BP CHART
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Systolic
BP
Diastolic
BP
Mean BP
Pulse
rate
Ephedrine
prn
co
21 22 23 24 25 26 27 28 29 30 35 40 45 50 55 60 65 70 80 90
Systolic
BP
Diastolic
BP
Mean BP
Pulse
rate
Ephedrine
prn
A p p e n d i x  D
EPHEDRINE TRIAL - Maternal condition Case no:
Name: No.:
Age: Weight: Fleight::
Indication for Caesarian section:_ 
Relevant history and examination:
Injection level:______________  Sensory level:
Fluids : pre-spinal_______ Blood loss: 
post-spinal______
total___________
Intra-operative symptoms: nausea___________
vomiting_________
pain_____________
Uterus: In/ Out
Times:IM injection_______________
Spinal injection____________
Skin incision______________
Uterine incision____________
Delivery_________________
Final skin suture_________ _
Baseline BP: Systolic______ Diastolic:
Mean:________  Pulse:__
Threshold: Assistant:
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A p p e n d i x  E
EPHEDRINE TRIAL - Foetal condition Case no:
Name:__________________
Weight:_______________  Premature/ Term
APGAR (pulse, respiration, colour, tone, reflex irritability)
1 min:________________
5 min:________________
Blood gas analysis:
Umbilical venous: pH ________________
pC02______________
p02________________
HC03______________
SBE_______________
Sat.________________
Other:
5 0
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